Tradestie Institutional Equity Comparison Engine
OBIO vs VIVS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OBIO Overall Edge
OBIO Captures Institutional Edge (3โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus VIVS at N/M Forward P/E and -10117.0% operating margin (-51.4% YoY). In options structure, OBIO sits in BREAKOUT (21st %ile IV; Dealer Gamma Walls on Pro) against VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
OBIO N/M vs VIVS N/M Fwd P/E
Growth & Margin Winner
OBIO
Op Margin -195.4% vs -10117.0% ยท YoY -89.4% vs -51.4%
Momentum & Technical Winner
OBIO
1Y +65.5% vs -87.0% ยท 52W Pos 81% vs 5%
Options & Structure Winner
OBIO
BREAKOUT (21st %ile IV) vs BREAKDOWN (N/A IV)
OBIO
NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.00
-6.17% 1D
Market Cap
$587.1M
1M Return
+20.59%
1Y Return
+65.48%
Forward P/E
N/M
Unified AI Score
37.8 / 100
SELL
Tech 50.0
Fund 36.0
Flow 68.0
Mom 50.0
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
OBIO +65.48%
VIVS -86.99%
Spread: +152.47 pp (OBIO Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | VIVS Revenue | OBIO Op. Margin | VIVS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -766.3% | VIVS |
| FY2019 | N/A | $0M | N/A | -882.4% | VIVS |
| FY2020 | N/A | $0M | N/A | -977.9% | VIVS |
| FY2022 | $0M | $0M | -924.3% | -765.3% | VIVS |
| FY2023 | $0M | $0M | -1866.2% | -4792.2% | OBIO |
| FY2024 | $0M | $0M | -2437.5% | -13840.4% | OBIO |
| FY2025 | $30M | $0M | -154.7% | -8761.1% | OBIO |
| FY2026 | N/A | $0M | N/A | -8768.7% | VIVS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OBIO | VIVS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $587.1M | $2.4M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -89.4% | -51.4% | Higher Growth | VIVS |
| Operating Margin (TTM) Profitability | -195.4% | -10117.0% | Higher Margin | OBIO |
| Net Profit Margin Profitability | -182.5% | 0.0% | Higher Margin | VIVS |
| Return on Equity (ROE) Capital Efficiency | -182.3% | -343.1% | Higher ROE | OBIO |
| 52-Week Range Position Momentum | 81% ($3โ$8) | 5% ($0โ$3) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 1.14ฮฒ ยท 86% Vol | 0.83ฮฒ ยท 480% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 37.8 / 100 (SELL) | 36.8 / 100 (SELL) | Higher Composite | OBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full OBIO vs VIVS Buy Guide
OBIO
BREAKOUT
35d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
21st %ile
IV Regime
Compressed (<25th %ile)
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither OBIO nor VIVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.